FDA Approves TRIKAFTA — Vertex Pharmaceuticals Incorporated

# FDA Approves Vertex Pharmaceuticals' TRIKAFTA for Cystic Fibrosis Vertex Pharmaceuticals Incorporated announced FDA approval of TRIKAFTA (elexacaftor, tezacaftor, and ivacaftor) on October 21, 2019, a triple-combination therapy expected to significantly expand the company's market reach within the cystic fibrosis treatment landscape and strengthen its position as a leader in CF care. The approval positions Vertex to capture a substantial portion of the estimated 30,000 CF patients in the U.S